Hormone Therapy Reduces Bone Resorption but not Bone Formation in Postmenopausal Athletes by Honisett, Suzy et al.
ПРИЛОЗИ. Одд. за мед. науки, XXXVII 2–3, 2016                                                                                                                               МАНУ 
CONTRIBUTIONS. Sec. of Med. Sci., XXXVII 2–3, 2016                                                                                                                     MASA 
 
ISSN 1857-9345 
UDC: 615.357.1:612.751.1.015.3 
612.751.1.015.3:615.357.1 
 
 
HORMONE THERAPY REDUCES BONE RESORPTION BUT NOT BONE 
FORMATION IN POSTMENOPAUSAL ATHLETES 
 
Suzy Y Honisett1, David Pagliaro1, Kathy Tangalakis1, Bronwyn Kingwell2, Peter Ebeling3, 
Robyn Craven4, Juliana Antonopillai1, Vasso Apostolopoulos1, Lily Stojanovska1,* 
 
1 Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne VIC 
Australia 
2 Baker Heart Research Institute, Prahran, VIC Australia 
3 Department of Diabetes, Endocrinology and Medicine, The University of Melbourne, The Royal 
Melbourne Hospital, Parkville, VIC Australia  
4 Women's Health and Breast Clinic, Freemasons Hospital, East Melbourne, VIC Australia 
 
Corresponding Author: Lily Stojanovska, Centre for Chronic Disease, College of Health and Biomedicine, St Albans 
Campus, Victoria University, VIC 3021, Australia; tel: +613 99192737; fax: tel: +613 99194565;  
e-mail: lily.stojanovska@vu.edu.au  
 
 
Abstract 
Introduction: Independently, hormone therapy and exercise have well-established protective effects 
on bone parameters. The combined effects of hormone therapy and exercise, however, are less clear. 
We, therefore, examined the effects of hormone therapy on bone turnover markers in postmeno-
pausal women undergoing regular high intensity exercise.  
Methods: In a randomised, double blind study, postmenopausal athletes competing at Masters level, 
received either hormone therapy (50 µg  transdermal oestradiol, 5 mg MPA, n = 8) or placebo (n = 
7) for 20 weeks. Women were tested before and after treatment for plasma concentrations of 
oestradiol, FSH, LH, and serum bone formation marker -osteocalcin (OC); and  urine bone 
resorption markers-pyridinoline (PYD) and deoxypyridinoline (DPD).  
Results: As a result of treatment with hormone therapy there were significant reductions in levels of 
FSH (73.3 ± 13.7 to 48.6 ± 10.5 mmol/L, p = 0.01) and bone resorption markers (PYD, 81.9 ± 7.7 to 
57.8 ± 3.7 nmol/mmol Cr, p = 0.001, and DPD, 18.5 ± 3.1 to 11.8 ± 2.1 nmol/mmol Cr, p = 0.01). 
Oestradiol and bone formation markers were not significantly altered as a result of hormone therapy. 
There were no changes to any variables with placebo treatment.  
Conclusion: Hormone therapy reduced bone resorption, but not bone formation, in postmenopausal 
athletes. These favorable reductions in bone turnover; therefore, provide an effective treatment in 
combination with high intensity exercise to further reduce the subsequent risk of osteoporosis and 
associated fractures. 
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Introduction 
Menopause is associated with an increase 
in bone turnover markers [1–3], and an eleva-
ted risk of osteoporotic fractures [1, 3, 4]. Hor-
mone therapy and exercise are 2 interventions 
commonly prescribed to ameliorate this risk. 
Estrogen administration has been shown 
to slow bone loss in postmenopausal women 
[5–7], providing protection against the deve-
lopment of osteoporosis and the risk of fracture 
[8]. This reduction in bone loss is apparent in 
measures of biochemical markers of bone for-
mation and resorption, with estrogen producing 
a net reduction in these markers [9, 10]. 
A number of meta-analysis studies have 
been conducted that assess the effects of phy-
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sical activity on bone loss in pre- and post- me-
nopausal women. High impact exercise increa-
ses bone mineral density (BMD) in premeno-
pausal women [11, 12], whereas, 8 months of 
Astanga yoga program provide beneficial effect 
on bone formation but did not improve BMD in 
premenopausal women. One study [13] found 
that the overall treatment effect of endurance 
training regimes prevented or reversed almost 
1% of bone loss per year in lumbar spine and 
femoral neck, whilst two other meta analyses 
[14, 15] found a beneficial effect of impact exer-
cise on the spine in post-menopausal women.  
Despite these positive independent asso-
ciations of exercise and hormone therapy on 
bone parameters, there are only  limited num-
ber of studies that have examined their com-
bined effects in a postmenopausal population. 
The potential benefits of physical activity in 
synergy with hormone therapy are inconsistent, 
and the results unclear [16, 17]. Prospective 
studies have reported improved bone mineral 
density (BMD) after initiating hormone therapy 
and exercise in previously sedentary postme-
nopausal women [16, 17]. However, it is diffi-
cult to ascertain in these studies what propor-
tions of the beneficial effects are attributable to 
initiating exercise or hormone therapy. Altho-
ugh this area is not new, it illustrates the need 
for a well-controlled approach to this topic, 
which addresses a direct comparison of exer-
cise with hormone therapy, whereby both inter-
ventions are carried out optimally. 
Herein, we determined whether hormone 
therapy would provide further improvement to 
bone turnover when given to postmenopausal 
women currently undertaking regular high in-
tensity weight bearing exercise. 
 
Methods 
Subjects 
Postmenopausal women were recruited 
from 'Masters' athletic running associations. 
Sixteen women were measured at baseline and 
fifteen women completed the study. The crite-
ria for inclusion were: 1–5 years postmenopau-
se; aged between 45–60 years; competing at 
'Masters' level in athletics, or vigorously run-
ning, jogging or cycling at least 4 times a week; a 
VO2 max of greater than 30 ml/min/kg2 which 
isconsidered very good to high cardio-respira-
tory fitness for age. The criteria for exclusion 
were: taking any form of hormone therapy; pre-
vious hysterectomy or oophorectomy; family 
history of malignancies; established cardiovas-
cular disease; smoking; excessive alcohol use 
or taking any drug therapy that would affect 
bone mineral and mineral metabolism. All wo-
men were cleared for participation following a 
full physical examination by a clinician. Rec-
ruited women were randomly assigned into two 
groups using a double blind design. Eight women 
were assigned into the 'ill group', and commen-
ced using transdermal oestradiol patches (Estra-
derm 50 µg twice/week, Novartis Pharmaceuti-
cals, North Ryde, NSW, Australia) and oral 
medroxyprogesterone acetate (MPA, 5 mg / day, 
Pharmacia Pharmaceuticals, Rydalmere, NSW, 
Australia). Seven women were assigned to the 
'placebo' group and commenced using placebo 
patches and oral placebo tablets. One woman 
dropped out of the study due to skin irritation 
caused by the trans-dermal patch. All women 
gave informed consent to participate in this stu-
dy, which was approved by the Human Ethics 
Committee, Victoria University (991017/CO484). 
Protocol 
All women underwent a number of mea-
sures at baseline (Tl) and at twenty weeks (T2). 
These included: blood samples for measurement 
of oestradiol, luteinising hormone (LH), follic-
le stimulating hormone (FSH), and the bone 
formation marker osteocalcin (OC), urine sam-
ples two hours post-first morning void for mea-
surement of the bone resorption markers pyri-
dinoline (PYD) and deoxypyridinoline (DPD); 
and aerobic capacity. Height, weight and body 
mass index (BMI) were also determined for all 
subjects. The above-mentioned biochemical mar-
kers of bone formation and resorption are of 
value in estimating bone turnover and have been 
used to reliably and consistently identify rapid 
bone losses [18]. Cross-sectional studies [3, 19] 
have shown that bone turnover rates, evaluated 
by these markers, increase at menopause and 
remain elevated, whilst bone turnover rates in 
postmenopausal women correlate negatively with 
BMD [20]. Participating subjects were reque-
sted to maintain their current training routine 
and diet throughout the study. 
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Assays 
Serum oestradiol was measured using a 
competitive chemiluminescent immunoassay 
(Gba-Coming, Medfield, MA, USA). FSH and 
LH were measured using a two-site chemilumi-
nescent (sandwich) immunoassay (Gba-Coming, 
Medfield, MA, USA). Serum OC was measured 
by radioimmunoassay using the osteocalcin RIA 
kit (Incstar Corp., Stillwater, MN, USA). Total 
PYD and DPD cross -links of type I collagen 
were measured in hydrolyzed urine samples by 
high performance liquid chromatography, correc-
ted for urine creatinine and expressed as nmol/ 
mmol Cr [1]. 
Aerobic Capacity (VO2 max) 
The laboratory where the trials were con-
ducted was maintained at a constant tempera-
ture (20 ± 1°Q and humidity (44 ± 2%). A 12 
lead ECG (Montara, X-scribe, Stress testing Sys-
tem, Milwaukee, USA) was used to monitor 
subjects' heart rhythm and rate throughout the 
duration of the test. Subjects exercised on a 
stationary bicycle ergometer (Cybex Metabolic 
System, Met 100, Huntsville, USA) at a constant 
cadence of 70 rpm. Increments in cycle resis-
tance occurred, commencing at 35 watts and 
increasing by 10 watts every minute. These in-
crements continued until the subject felt they 
could not continue due to exhaustion, or until 
the subject experienced discomfort, or the prac-
titioner stopped the test for medical reasons. 
Each subjects' oral gas expiration was measu-
red via Vacumetric Vista Turbofit Software pac-
kage (Version 3.2, Ametek, Pittsbergh, USA) 
to determine their respiratory exchange ratio 
(RER) and VO2 max. Both variables were sub-
sequently charted throughout the duration of 
the exercise to ensure that their aerobic thre-
shold was reached. Subjects were expected to 
have reached their VO2 max (a measure of ma-
ximal aerobic capacity) when at least two of 
the following criteria were achieved (a) a pla-
teau of VO2 max readings, (b) exercising heart 
rate to within 10 beats of subjects' maximal 
heart rate, (c) an RER of greater than 1.10. 
Statistical Analysis 
The data were analysed using Sigma Stat. 
2.0 Gandell, USA). The data are reported at ba-
seline as mean ± standard error of the mean 
(SEM). Changes to variables with treatment are 
reported as percent change from baseline. A 
Student's paired t-test was used to determine 
significance of changes with treatment. At-test 
was used to determine differences between tre-
atment groups at baseline. Significance was re-
ported as p < 0.05. 
 
Results 
There were no significant differences bet-
ween the two groups at baseline for: age, BMI, 
VO2 max, serum oestradiol and gonadotrophin le-
vels, OC and DPD (Table 1). Urine PYD was sig-
nificantly higher in the HRT group compared at ba-
seline with the placebo group (p = 0.03) (Table 1). 
 
Table 1 
 
Baseline groups characteristics in the two groups of postmenopausal athletes 
 
 
Variable Placebo N = 7 
Hormone 
Therapy 
N = 8 
Age, years 54.7  1.3 53.8  1.8 
BMI, kg.m2 22.2  1.2 23.5  1.2 
Estradiol, mmol/L 76.1  12.1 55.1  26.1 
FSH, mmol/L 70.8  13.5 73.3  13.7 
LH, mmol/L 38.2  6.7 40.9  9.1 
VO2 max, ml/kg/min 35.6  3.0 35.2  2.0 
Osteocalcin, U/L 32.5  9.9 31.2  10.2 
PYD, nmol/mmol Cr 64.0  7.0 81.9  7.3* 
DPD, nmol/mmol Cr 13.4  1.8 18.5  3.1 
Values are mean  SEM. BMI indicates body mass index; FSH, follicle stimulating hormone; LH, luteinising 
hormone; VO2 max, maximal aerobic capacity; PYD, pyridinoline; DPD, deoxypyridinoline. * indicates a significant 
difference, p < 0.05, between groups 
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After 20 weeks of treatment, there were no 
significant changes in any parameter in the pla-
cebo group. However, in the HRT group FSH 
levels significantly decreased (73.3 ± 13.7 to 48.6 
± 10.5 mmol/L, p = 0.01, mean ± SEM) indicating 
that subjects were compliant with HRT. Medica-
tion compliance was verified by medication counts.  
VO2 max was unchanged in both groups 
(HRT group 35.2 ± 2.0 to 37.0 ± 2.1 ml/kg/min, 
p = 0.27; placebo group 35.6 ± 3.0 to 34.6 ± 
3.6 ml/kg/min, p = 0.66) indicating that sub-
jects maintained their existing exercise training 
regimen and fitness level throughout the dura-
tion of the trial. The bone formation marker, 
OC, remained unchanged with HRT admini-
stration (31.26 ± 10.2 to 32.3 ± 11.8, p = 0.53). 
However, there were significant reductions in 
both bone resorption markers after 20 weeks of 
HRT, with PYD decreasing by 27.3% (81.9 ± 
7.3 to 57.8 ± 3.7, p = 0.001) and DPD decrea-
sing by 33.0% (18.5 ± 3.1 to 11.8 ± 2.1, p = 
0.01) from baseline (Figure 1). 
 
 
 
Figure 1 – Percentage change from baseline in resorption markers with placebo (white) and hormone replacement 
therapy (HRT) (black) treatment in postmenopausal athletes 
 
Discussion 
The results of this study demonstrate that 
athletically trained postmenopausal women are 
able to significantly reduce bone resorption with 
the use of hormone therapy; indicating that a 
combined intervention exceeds the effects of 
exercise alone on bone.  
Many older women are involved in endu-
rance-based exercises such as running, jogging 
and cycling, and compete at 'Masters' level ath-
letics. For these women skeletal integrity is an 
important issue that may affect their continued 
performance in their chosen event after meno-
pause. An improvement in BMD is shown with 
endurance exercise [13]; however, this form of 
exercise is not as effective as resistance or we-
ight training [21]. Animal studies have shown 
that maximal osteogenesis occurs with high-
magnitude strains applied with few strain cyc-
les, as performed with resistance training [22–
25]. Moreover, in a postmenopausal osteoporo-
sis rat model, exercise significantly increased 
bone mass by both inhibiting bone resorption 
and increasing bone formation in trabecular bo-
nes [26]. Therefore, to assist in the mainte-
nance and/or improvement of skeletal integrity 
after menopause, hormone therapy is a viable 
option. 
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There have been a number of prospective 
studies assessing the effect of combined treat-
ment on BMD in postmenopausal women yiel-
ded conflicting results [16, 17]. One study iden-
tified that weight bearing exercise and hormone 
therapy independently increased BMD at sites 
of lumbar spine and proximal femur, while a 
combined treatment provided an additive effect 
on BMD at lumbar spine and was synergistic 
for total body BMD [16]. Another study has 
shown that combined resistance training and 
hormone therapy increased BMD at sites of 
radial mid-shaft, spine and total body, while 
hormone therapy alone was associated with no 
change, or bone maintenance, after one year [17]. 
The effect of exercise alone was not measured 
in this study making it difficult to assess whe-
ther BMD accretion was due to the combina-
tion of treatments or due to the effect of exer-
cise alone. In contrast to these studies, another 
prospective study found moderate exercise alo-
ne, including weight lifting, provided no chan-
ges in BMD, whilst the combination of exer-
cise and hormone therapy provided no greater 
benefit in comparison to hormone therapy alo-
ne [27]. All of these studies introduced exercise 
in previously sedentary women, making it dif-
ficult to determine whether any changes in 
bone status were due to the initiation of exer-
cise or the commencement of hormone therapy. 
None of the studies addressed endurance based 
exercise regimes. One recent cross-sectional 
study investigating 'Masters' trained postmeno-
pausal athletes found that the women replacing 
estrogen had greater BMD of the hip, spine and 
total body compared with athletes not replacing 
estrogen [28]. However, years post-menopause 
were significantly greater in the women not re-
placing estrogen, possibly affecting BMD va-
lues and limiting the conclusions from this study. 
The present study investigated women 
currently involved in endurance-based weight 
bearing exercises and provided a direct com-
parison of interventions using a well-controlled 
approach. This study assessed the impact of 
hormonal therapy treatment for 20 weeks on 
bone turnover markers that, to the best of our 
knowledge, have not been addressed in this po-
pulation of postmenopausal athletes before. 
Interestingly in this population of post-
menopausal athletes, hormone therapy for 20 
weeks provided added benefit to bone status by 
significantly decreasing bone resorption but not 
bone formation, suggesting that these interven-
tions may be highly effective when used in 
combination to further reduce the risk of bone 
loss and osteoporotic fracture. Larger control-
led prospective studies of longer duration are 
required to assess effects of hormonal therapy 
and endurance-based weight bearing exercise 
on bone density. 
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Ре зиме 
 
ХОРМОНСКАТА ТЕРАПИЈА  
ЈА НАМАЛУВА КОСКЕНАТА 
РЕСОРПЦИЈА, НО НЕ И ФОРМИРАЊЕТО 
НА КОСКИТЕ КАЈ АТЛЕТИ  
ВО ПОСТМЕНОПАУЗА 
 
Сузи Ј Хонисет1, Дејвид Палјаро1,  
Кети Тангалакис1, Бронвин Кингвел2,  
Петер Ебелинг3, Робин Крејвен4,  
Џулијана Антонопилаи4,  
Васо Апостолопулос1, Лили Стојановска1 
 
1 Центар за хронични болести, Школа  
за здравство и биомедицина, Универзитет 
Викторија, Викторија, Австралија 
2 Истражувачки институт „Бејкер Харт“, 
Прахран, Викторија, Австралија 
3 Оддел за дијабетес, ендокринологија  
и медицина, Универзитет во Мелбурн,  
Кралска болница во Мелбурн, Парквил, 
Викторија, Австралија 
4 Клиника за здравје на жените и дојките, 
болница „Фримејсон“, Источен Мелбурн, 
Викторија, Австралија 
 
 
Вовед: Независно, хормонската терапија и 
вежбањето имаат добро воспоставени заштитни 
ефекти врз коскените параметри. Сепак, комби-
нираните ефекти на хормонската терапија и веж-
бањето се помалку јасни. Затоа, ги испитувавме 
ефектите на хормонската терапија на маркери 
на коскениот метаболизам кај жени во пост-
менопауза подложени на редовни високо интен-
зивни вежби.  
Методи: Во рандомизирана, двојно слепа 
студија, атлетите во постменопауза кои се нат-
преваруваат на ниво на Мастер, 20 недели при-
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мале или хормонска терапија (50 μg трансдер-
мален естрадиол, 5 mg МПА, n = 8) или плацебо 
(n = 7). Жените беа тестирани пред и по трет-
манот за плазма концентрациите на естрадиол, 
FSH, LH и серумскиот маркер за формирање на 
коска – остеокалцин (OC); и уринскиот маркер 
за коскена ресорпција – пиридинолин (PYD) и 
деоксипиридинолин (DPD). 
Резултати: Како резултат на третманот 
со хормонската терапија имаше значително на-
малување на нивото на FSH (73,3 ± 13,7 до 48,6 
± 10,5 mmol / L, p = 0,01) и маркерите за коскена 
ресорпција (PYD, 81,9 ± 7,7 до 57,8 ± 3,7 nmol / 
mmol Cr, p = 0,001, и DPD, 18.5 ± 3,1 до 11,8 ± 
2,1 nmol / mmol Cr, p = 0,01). Естрадиолот и 
маркерите за формирање на коските не беа зна-
чително променети како резултат на хормон-
ската терапија. Немаше промени кај кои било 
варијабли со плацебо третманот.  
Заклучок: Хормонската терапија ја намали 
коскена ресорпција, но не и формирањето на 
коските, кај атлетите во постменопауза. Овие 
поволни намалувања на коскениот метаболизам   
обезбедуваат ефективен третман во комбинаци-
ја со високиот интензитет на вежбање за ната-
мошно намалување на последователниот ризик 
од остеопороза и поврзани фрактури. 
 
Клучни зборови: вежба, менопауза, коскен метабо-
лизам, хормонска заменска терапија, естрадиол 
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